Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
Received 27 October 2017
Accepted for publication 4 December 2017
Published 10 April 2018 Volume 2018:11 Pages 73—79
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr Luis Garcia-Marcos
Jie Gao, Zhaocheng Chen, Xiang Jie, Ruihua Ye, Feng Wu
Department of Respiratory Medicine, The Third People’s Hospital, Guangzhou Medical College, Huizhou, People’s Republic of China
Background: Sputum eosinophil and fractional exhaled nitric oxide (FeNO), noninvasive biomarkers of local eosinophilic airway inflammation, can be used to assess asthma outcome. Nevertheless, the clinical application of the association between FeNO and sputum eosinophil is controversial. The aim of the study was to investigate the predictive relationship between FeNO and sputum eosinophil in uncontrolled asthmatic patients and the correlation between sputum eosinophil and FeNO in bronchial reversibility and bronchial hyperresponsiveness (BHR).
Methods: A total of 69 uncontrolled asthmatic patients were included in the study. All patients underwent a clinical assessment on the same day as follows: FeNO, spirometry with BHR or bronchodilator reversibility test and induced sputum in turn. Eosinophilic airway inflammation was defined as sputum eosinophil percentage (≥2.5%)/FeNO level (≥32 parts per billion [ppb]).
Results: FeNO level and sputum neutrophilic percentage were higher in the sputum eosinophilia group compared to those without (49 versus 27, p=0.011; 71.12 versus 87.67, p=0.012, respectively). Sputum eosinophil percentage was higher with raised FeNO level compared to those without (10.3% versus 2.75%, p=0.03). A significant correlation was observed between sputum eosinophil percentage and FeNO level (r=0.4016; p=0.0006). There were no significant relationships between sputum eosinophilic percentage and provocative dose (PD20)/∆FEV1 (improvement in a forced expiratory volume in 1 second [FEV1] after 400μg of salbutamol), FeNO levels and PD20/∆FEV1. The FeNO level of 35.5 ppb was effective in assessing sputum eosinophilia, with a receiver operating characteristic area under curve (AUC) of 0.707 (p=0.011; 95% confidence interval [CI] 0.573–0.841), and 4.36% was the best diagnostic cutoff value of sputum eosinophil percentage for the FeNO level of 32 ppb (AUC 0.721; 95% CI 0.59–0.852).
Conclusion: FeNO level can accurately detect eosinophilic asthma but has limited value to assess noneosinophilic asthma in uncontrolled stage. Further studies are required to validate the use of FeNO level to determine an optimal cutoff for sputum eosinophilia that could be used in clinical practice.
Keywords: FeNO, sputum eosinophil, bronchial reversibility, BHR, asthma
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]